) in all but one patient treated with pulsed ATRA therapy. These data were confirmed with qualitative and quantitative RT-PCR. After a median follow-up of 17 months from the start of ATRA therapy, 4/5 patients (80%) are in continuous complete molecular remission. To our knowledge, this is the first clinical observation that intermittent ATRA therapy (without chemotherapy) is effective not only in inducing but also in maintaining long-term molecular remission in APL patients. This approach could therefore be effective, if confirmed in larger series, in relapsed/refractory patients unsuitable for high-dose therapy and SCT; it may be proposed as induction therapy for selected older APL patients if considered not to be eligible for combined ATRA/CHT due to inadequate performance status or concurrent disease. Leukemia (2001) 15, 1696-1700.
Introduction
Acute promyelocytic leukemia (APL) is characterized by a specific balanced translocation where the gene for PML on chromosome 15 is fused with the retinoic acid receptor-alpha (RAR-␣) gene on chromosome 17. [1] [2] [3] The resulting PML-RAR␣ fusion protein induces the leukemic transformation of myeloid cells. 4, 5 Expression of PML-RAR␣ fusion mRNA provides a sensitive marker that can be detected using reverse transcription-polymerase chain reaction (RT-PCR) amplification. The qualitative RT-PCR is useful in the diagnosis of APL and in the detection of minimal residual disease (MDR) after induction of clinical complete remission (CR) and as a prediction of relapse. [6] [7] [8] [9] However, the recent introduction of quantitative real time RT-PCR 10 should allow quantitation of the target gene to be routinely performed at diagnosis and during followup. In real time RT-PCR, the 5′-3′ nuclease activity of the Taq polymerase cleaves a fluorogenic probe specific for the target sequence, causing the emission of a fluorescent signal that can be detected during amplification. This allows the identification and quantitation of specific RT-PCR products as the reaction proceeds. Several groups have used real time RT-PCR with TaqMan tecnology to quantitate MDR with leukemiaspecific chromosome aberrations other than PML-RAR␣, such as t(9;22) and t(8;21). 11, 12 All-trans retinoic acid (ATRA) and anthracyclines are the mainstays of treatment of newly diagnosed APL. 13 APL cells respond to treatment with terminal granulocytic differentiation followed by cell death. [11] [12] [13] [14] Oral ATRA induces clinical and hematologic remission in the vast majority of patients. 15, 16 However, the continuous administration of ATRA as single agent is almost invariably associated with the reappearance of the disease, 12, [15] [16] [17] due to the occurrence of acquired mechanisms of resistance. 8, 9, 12, [15] [16] [17] [18] [19] [20] The high incidence of relapse induced clinical investigators to combine ATRA with chemotherapy (CHT), mainly during induction of CR and maintenance. Although the combined treatment is able to induce and maintain remissions in up to 70% of newly diagnosed patients, there are a number of APL patients that either fail to reach molecular remission after induction/consolidation, or experience a molecular relapse after the end of maintenance treatment. In addition, CHT, although generally well tolerated, is not devoid of risks, especially in elderly patients and particularly if they are pretreated. As a consequence, selected patients either at diagnosis or in hematological and cytogenetic but not molecular remission after previous therapy are not suitable for a combined ATRA/CHT treatment.
On the other hand, in vitro studies have shown that discontinuing the administration of ATRA may result in the reversal of some of the acquired mechanisms of resistance. 12, [15] [16] [17] We have therefore studied the effects of intermittent ATRA administration in five molecularly positive APL patients in different phases of the disease, analyzing the effects of therapy with qualitative and quantitative RT-PCR.
Patients and methods

Patients
Five patients, diagnosed between 1995 and 1999, were studied (Table 1) . Four out of the five patients were untreatable with other chemotherapy regimens, mainly due to their clinical condition and to previous toxicity. One patient refused further chemotherapy cycles. All the patients were enrolled with a view to treatment with pulsed ATRA, followed by auto-SCT. Only one patient (No. 4) was able to complete this program. Regarding the others, one patient (No. 1) found a suitable (familiar) donor for allo-SCT and refused auto-SCT, two patients (Nos 2 and 3) were too old to be eligible for auto-SCT, whilst patient No. 5 relapsed before an auto-SCT was feasible. Four out of five started the pulsed ATRA regimen after documentation of persistent molecular positivity (after consolidation (patient Nos 4 and 5), or after induction therapy (pt No. 3), or reappearance of molecular relapse after the end of maintenance (pt No. 1)). They had all previously entered into the multicentric GIMEMA-AIEOP AIDA trial: (Table 1) . After induction therapy (ATRA + CHT), plus three cycles of consolidation chemotherapy (a transient molecular negativity (one determination) was observed, followed after 1 month by molecular positivity).
Leukemia
Pulsed ATRA regimen ATRA (45 mg/m 2 /day) was administered daily for 3 weeks and thereafter at the same dose in continuous cycles with 1 week on and 2 weeks off. Discontinuation of therapy was scheduled if progression of the disease (cytogenetic or morphological relapse) was documented.
Samples and RNA isolation
Bone marrow mononuclear cells aspirated from the posterior iliac crest were obtained by Ficoll-Hypaque density gradient centrifugation and stored at −80°C in guanidinium thyocyanate. Total cellular RNA was extracted as previously described. 23 
Qualitative RT-PCR
Qualitative RT-PCR was routinely performed at diagnosis and during follow-up as previously described in the BIOMED-1 Concerted Action protocol. This is an assay with a sensitivity of one positive cell out of 10 3 -10 4 cells. 24 
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was retrospectively performed. The principles and procedure of real time RT-PCR quantitation using the TaqMan probe have been previously described.
10,25,26
Primers and probes: Table 2 and Figure 1 report the primers and probes used for real time RT-PCR quantification of the PML-RAR␣ fusion gene and the ABL gene. Probes were labeled with a 5′ FAM reporter and 3′ TAMRA quencher. Primers and TaqMan probes were all designed using Primer Express software (Perkin Elmer, Foster City, CA, USA). CCA GTA GCA TCT GAC TTT GAG CCT CAG GG ABL exon 2
Figure 1
Primers and probes used for real-time RT-PCR of t(15;17) and ABL.
PCR conditions:
Reaction mixtures of 25 l contained 12.5 l of TaqMan buffer A with the ROX dye as the passive reference, 5 mm MgCl 2 , 200 m dATP, dCTP, dGTP, 400 m dUTP, 1.25 U AmpliTaq Gold DNA polymerase, 0.5 U AmpErase uracil N-glycosylase (UNG), 300 nm forward and reverse primers, 200 nm specific TaqMan probe and 6 l of plasmid or cDNA (diluted 1:3). All the reagents were from Perkin Elmer/Applied Biosystem.
RT-PCR reactions were set in MicroAmp optical 96-well reaction plates closed with MicroAmp optical caps (Perkin Elmer/Applied Biosystem). After 2 min at 50°C to allow the destruction by UNG of potentially contaminated RT-PCR products, and 10 min at 95°C to denature UNG and activate AmpliTaq Gold, the amplification was carried out for 50 cycles at 95°C for 15 s and 65°C for 60 s in the ABI/Prism 7700 Sequence Detector System (ABI/Perkin Elmer, Foster City, CA, USA).
Results
Four out of five APL patients were in clinical and morphological CR when the treatment with pulsed ATRA was started, with the fifth patient at diagnosis (Table 1 ). All five patients had qualitative RT-PCR measured routinely. Pulsed ATRA regimen as single therapy was able to convert their positive RT-PCR to a negative RT-PCR after a median time of 3 months (range 1-15). Quantitative RT-PCR was used to monitor the disappearance of the leukemic fusion transcript and also to confirm it. The sensitivity of this assay was one positive cell out of 10 3 cells. 26 It became apparent that the quantity of transcript was directly related to pulsed ATRA administration. This quantity decreased progressively from the beginning of therapy. In patients 2 and 3 the amount of PML-RAR␣/ABL showed a one log decrease and became and remained negative according to the sensitivity of our qualitative assay (Figures 2 and 3) . In particular, in patient No. 4 the amount of PML-RAR␣/ABL was undetectable after 4 months from the beginning of ATRA ther-
Figure 4
Qualitative and quantitative RT-PCR follow-up: pt No. 4 received pulsed ATRA therapy after induction therapy (ATRA + CHT), plus three cycles of consolidation chemotherapy.
Figure 5
Qualitative and quantitative RT-PCR follow-up: pt No. 5 received pulsed ATRA therapy after induction therapy (ATRA + CHT), plus three cycles of consolidation chemotherapy (a transient molecular negativity (one determination) was observed, followed after 1 month by molecular positivity).
Figure 6
Qualitative and quantitative RT-PCR follow-up: pt No. 1 received pulsed ATRA therapy after induction therapy (ATRA + CHT), plus three cycles of consolidation chemotherapy, plus 2 years of maintenance (ATRA + CHT) and 9 months off therapy. apy ( Figure 4) . In patient No. 5, there was a one log decrease in the level of PML-RAR␣/ABL which persisted for a few months, after which there was a molecular relapse detected with qualitative RT-PCR and associated with a two log rise in the level of PML-RAR␣/ABL ( Figure 5 ). Interestingly, in patient No. 1 qualitative RT-PCR proved to be a more sensitive assay than quantitative RT-PCR (as shown in Figure 6 ), as the quantity of PML-RAR␣/ABL was undetectable at a time when qualitative RT-PCR was positive.
After a mean follow-up of 17 months (range 1-20) from the beginning of ATRA therapy, four out of five patients were RT-PCR negative.
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The toxicity of the regimen was minimal; no adverse effects were observed, except for mild headache during ATRA administration in two out of five patients; all patients were able to continue the treatment as planned without discontinuing the drug.
Discussion
ATRA as single continuous therapy induces CR in a substantial proportion of newly diagnosed APL patients. However, remissions have typically lasted no more than a few months, due to the rapid development of retinoid resistance. This could be due to various mechanisms, including an increase in cellular acid binding protein levels, mutations occurring in the RAR␣ region of the PML-RAR␣ fusion gene during ATRA therapy, or serum concentrations decreasing within a short period of time after the beginning of therapy. 12, [15] [16] [17] The occurrence of ATRA resistance, therefore, has to be considered when planning therapy. Currently adopted protocols for APL patients provide an induction phase based on simultaneous ATRA and anthracycline-containing chemotherapy, a consolidation phase based on chemotherapy alone, and a maintenance phase. This latter treatment phase can be based on chemotherapy alone or on chemotherapy alternated with ATRA. These therapeutic approachs are still under evaluation and whether the addition of chemotherapy to ATRA during maintenance is beneficial for APL patients has yet to be demonstrated. Although the combined treatment with anthracycline-based chemotherapy and ATRA is able to induce and maintain remissions in up to 70% of newly diagnosed patients, there are a number of APL patients that either fail to reach molecular remission after induction/consolidation, or experience a molecular relapse after the end of maintenance treatment. The current approach for the treatment of these cases is to try to reinduce remission either with experimental therapies (ie arsenic trioxide) or with ATRA coupled with intensive chemotherapy, followed by auto-or allo-SCT, depending on the availability of an HLA suitable donor. Chemotherapy, however, although usually well tolerated, is not devoid of risks, especially in elderly patients and in particular if they have been pretreated. As a consequence, selected patients either at diagnosis, or re-experiencing molecular positivity after previous therapy, are not suitable for a combined ATRA/CHT treatment.
Bearing this in mind, we developed a treatment strategy based on intermittent use of ATRA. The therapy resulted in a complete cytogenetic and molecular remission, ranging from 1 to 21 months in duration in all five patients. Molecular remission was further confirmed by quantitative RT-PCR, showing a progressive reduction to a negligible quantity in the level of PML-RAR␣ fusion transcript in all but one of the patients treated with ATRA (patient No. 5; molecular complete remission duration 1 month), in which the rapid reappearance of the disease was associated with a concomitant amount in the quantity of the transcript. Quantitative RT-PCR appears, therefore, as previously demonstrated in other diseases, to be a promising method to finely control minimal residual disease in APL.
It should be noted that one patient treated with ATRA alone at diagnosis (pt 2; intermittent ATRA administration from diagnosis until now) is still experiencing a condition of molecular remission (20 months), which represents one of the longest complete molecular remissions ever obtained, without additional chemotherapy in first-diagnosed APL.
As previously stated, the causes of retinoid resistance are not all due to mechanisms related to continuous treatment, limiting the applicability of an intermittent ATRA administration. This therapeutic schedule still deserves further evaluation, expecially in patients who, having discontinued ATRA therapy for more than 1 month, re-experienced molecular positivity, as it is possible to observe after consolidation or after maintenance. In fact, our results suggest that the intermittent administration of ATRA induces or reinduces long-lasting molecular remission, challenging the role of chemotherapy. This approach could therefore be effective in relapsed/ refractory patients unsuitable for high-dose therapy and SCT, if confirmed in larger studies, and could be proposed as induction therapy for selected older APL patients not eligible for combined ATRA/CHT due to inadequate performance status or concurrent disease.
